Hepatitis C virus-related lymphoproliferative disorders: An overview

Table 2 IFN monotherapy in HCV-related mixed cryoglobulinemia

Author	Year	No. patients	Treatment	CS	Treatment duration (months)	EOT response	Sustained response
Ferri	1993	15	2 MIU IFN/d (1 m) – 2 MIU IFN × 3/w (5 m)	Yes	6	80%
Ferri	1993	26	2 MIU IFN/d (1 m) – 2 MIU IFN × 3/w (5 m)	Yes	6	100%	0
Marcellin	1993	2	3 MIU IFN × 3/w		6	50%
Johnson	1993	4	1-10 MIU IFN	No	2-12	75%1
Misiani	1994	27	1.5 MIU IFN × 3/w (1 w) – 3 MIU IFN × 3/w (23 w)	No	6	60%	0
Dammacco	1994	15	3 MIU IFN × 3/w	No	12	53.30%	25%
		16	3 MIU IFN × 3/w	Yes	12	52.90%	33.30%
Johnson	1994	14	Variable IFN	No		01
Mazzaro	1994	18	3 MIU IFN × 3/w	No		28%
Mazzaro	1995	18	3 MIU IFN × 3/w	No	6	28%	11%
		18	3 MIU IFN × 3/w	No	12	39%	22%
Casaril	1996	25	6 MIU IFN × 3/w	No	6	52%2
Cohen	1996	20	3 MIU IFN × 3/w			60%3	9%3
Akriviadis	1997	20	3-5 MIU IFN × 3/w	No	6-12	65%2	33%2
Casato	1997	31	3 MIU IFN/d (3 m) – 3 MIU IFN × 3/w (≥ 9 m)	No	≥ 12	62%

CS: corticosteroids; MIU: millions of international units; d: daily; m: months; w: week; EOT: end of treatment; ^s: Kidney function improvement;

²: Cryoglobulins disappearance,

³: both complete and partial MC syndrome response. From: Zignego A.L. Postgraduate Course of the 41st Annual Meeting of the EASL, 2006, modified.